Trust Fund — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Nectarmynectar.comJun 2025 · $10.6M
Nectar Allergy & Asthma is an allergy care platform offering testing, diagnosis, and treatment for food and environmental allergies, asthma, and eczema, including at-home testing kits and custom sublingual immunotherapy drops.
Digital HealthDirect to ConsumerHealthtechNew York City, US
Hersh Patel(Founder)in
Co-investorsGold House VenturesHarmony PartnersObvious VenturesMenlo Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.